Pascal van Elzakker

Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity

C. B. H. W. Lamers, Stefan Sleijfer, Sabine van Steenbergen et al. · Molecular Therapy · 2013 · 709 citations · Full text

Medicine, Immunology, Oncology +17

Immune responses to transgene and retroviral vector in patients treated with ex vivo–engineered T cells

C. B. H. W. Lamers, Ralph A. Willemsen, Pascal van Elzakker et al. · Blood · 2010 · 367 citations · Full text

Life Sciences, Immunology, Translational Sciences +16

Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer

C. B. H. W. Lamers, Ralph A. Willemsen, Pascal van Elzakker et al. · Cancer Gene Therapy · 2005 · 38 citations

Life Sciences, Immunology, Oncology +17

Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene

C. B. H. W. Lamers, Pascal van Elzakker, S.C.L. Langeveld et al. · Cytotherapy · 2006 · 35 citations

Medicine, Immunology, Oncology +17

Retronectin®-assisted retroviral transduction of primary human T lymphocytes under good manufacturing practice conditions: tissue culture bag critically determines cell yield

C. B. H. W. Lamers, Pascal van Elzakker, Sabine C.L. van Steenbergen et al. · Cytotherapy · 2008 · 22 citations

Life Sciences, Biotechnology, Immunology +14